Bristol-Myers Squibb announced plans to lay off 4,300 employees and close more than half of its manufacturing plants in a cost-saving, "right-sizing" move. Followed by Pfizer and Merck, it's the third big pharma company to take action against the looming generics competition. In the Pipeline's Derek Lowe thinks it's not a bad thing, as long as R&D is left alone to do what they do best -- discover new drug compounds.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.